Oral fosfomycin formulation for acute bacterial prostatitis; a new role for an old molecule: A case report and brief literature review

Marino,Andrea; Stracquadanio,Stefano; Ceccarelli,Manuela; Zagami,Aldo; Nunnari,Giuseppe; Cacopardo,Bruno

doi:10.3892/wasj.2022.161

Oral fosfomycin formulation for acute bacterial prostatitis; a new role for an old molecule: A case report and brief literature review

Authors:
- Andrea Marino
- Stefano Stracquadanio
- Manuela Ceccarelli
- Aldo Zagami
- Giuseppe Nunnari
- Bruno Cacopardo
View Affiliations

Affiliations: Department of Biomedical and Biotechnological Sciences, University of Catania, I‑95123 Catania, Italy, Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, I‑95123 Catania, Italy, Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, I‑98122 Messina, Italy
Published online on: June 15, 2022 https://doi.org/10.3892/wasj.2022.161
Article Number: 26
Copyright: © Marino et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute and chronic bacterial prostatitis are considered infections which are cumbersome to treat, due to the limited available selection of effective antibiotics and the pharmacologically poor distribution in prostatic tissue. Furthermore, the emergence of novel antimicrobial resistance patterns, such as extended spectrum β‑lactamase (ESBL)‑producing Escherichia coli (E. coli) along with increasing fluoroquinolone resistance poses major clinical concerns in selecting the appropriate therapy to treat and eradicate the infection, particularly considering the outpatient setting. The present study describes the case of a healthy male affected by a first acute bacterial prostatitis episode due to ESBL‑producing E. coli. The patient was successfully treated with oral fosfomycin‑trometamol administration, achieving clinical success with microbiological eradication. The case described in the present study, along with the literature review, encourage and suggest the use of oral fosfomycin for the treatment of both acute and chronic prostatitis, particularly for outpatients and for those subjects who cannot be administered other antibiotics.

View Figures

View References

1	Bouiller K, Zayet S, Lalloz PE, Potron A, Gendrin V, Chirouze C and Klopfenstein T: Efficacy and safety of oral fosfomycin-trometamol in male urinary tract infections with multidrug-resistant enterobacterales. Antibiotics (Basel). 11(198)2022.PubMed/NCBI View Article : Google Scholar
2	Kwan ACF and Beahm NP: Fosfomycin for bacterial prostatitis: A review. Int J Antimicrob Agents. 56(106106)2020.PubMed/NCBI View Article : Google Scholar
3	Erdem H, Hargreaves S, Ankarali H, Caskurlu H, Ceviker SA, Bahar-Kacmaz A, Meric-Koc M, Altindis M, Yildiz-Kirazaldi Y, Kizilates F, et al: Managing adult patients with infectious diseases in emergency departments: International ID-IRI study. J Chemother. 33:302–318. 2021.PubMed/NCBI View Article : Google Scholar
4	El-Sokkary R, Uysal S, Erdem H, Kullar R, Pekok AU, Amer F, Grgić S, Carevic B, El-Kholy A, Liskova A, et al: Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: An international ID-IRI survey. Eur J Clin Microbiol Infect Dis. 40:2323–2334. 2021.PubMed/NCBI View Article : Google Scholar
5	Marino A, Munafò A, Zagami A, Ceccarelli M, Di Mauro R, Cantarella G, Bernardini R, Nunnari G and Cacopardo B: Ampicillin plus ceftriaxone regimen against enterococcus faecalis endocarditis: A literature review. J Clin Med. 10(4594)2021.PubMed/NCBI View Article : Google Scholar
6	Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 18:268–281. 2012.PubMed/NCBI View Article : Google Scholar
7	Aris P, Boroumand MA, Rahbar M and Douraghi M: The activity of fosfomycin against extended-spectrum beta-lactamase-producing isolates of enterobacteriaceae recovered from urinary tract infections: A single-center study over a period of 12 years. Microb Drug Resist. 24:607–612. 2018.PubMed/NCBI View Article : Google Scholar
8	Falagas ME, Kastoris AC, Kapaskelis AM and Karageorgopoulos DE: Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, enterobacteriaceae infections: A systematic review. Lancet Infect Dis. 10:43–50. 2010.PubMed/NCBI View Article : Google Scholar
9	Zhanel GG, Zhanel MA and Karlowsky JA: Oral Fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by multidrug-resistant Escherichia coli. Can J Infect Dis Med Microbiol. 2018(1404813)2018.PubMed/NCBI View Article : Google Scholar
10	Marino A, Munafò A, Zagami A, Ceccarelli M, Campanella E, Cosentino F, Moscatt V, Cantarella G, Di Mauro R, Bernardini R, et al: Ampicillin plus ceftriaxone therapy against enterococcus faecalis endocarditis: A case report, guidelines considerations, and literature review. IDCases. 28(e01462)2022.PubMed/NCBI View Article : Google Scholar
11	Devrim I, Erdem H, El-Kholy A, Almohaizeie A, Logar M, Rahimi BA, Amer F, Alkan-Ceviker S, Sonmezer MC, Belitova M, et al: Analyzing central-line associated bloodstream infection prevention bundles in 22 countries: The results of ID-IRI survey. Am J Infect Control. (S0196-6553(22)00138-9)2022.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
12	Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J and Kamerling IMC: Fosfomycin: Pharmacological, clinical and future perspectives. Antibiotics (Basel). 6(24)2017.PubMed/NCBI View Article : Google Scholar
13	MIC EUCAST: Antimicrobial Wild Type Distributions of Microorganisms. Available from: https://mic.eucast.org/search/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=100&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50. Accessed May 9, 2022.
14	Sastry S and Doi Y: Fosfomycin: Resurgence of an old companion. J Infect Chemother. 22:273–280. 2016.PubMed/NCBI View Article : Google Scholar
15	Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, Frauman AG and Grayson ML: Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 58:e101–e105. 2014.PubMed/NCBI View Article : Google Scholar
16	Fan L, Shang X, Zhu J, Ma B and Zhang Q: Pharmacodynamic and pharmacokinetic studies and prostatic tissue distribution of fosfomycin tromethamine in bacterial prostatitis or normal rats. Andrologia. 50(e13021)2018.PubMed/NCBI View Article : Google Scholar
17	Takasaki N, Ra S, Okada S, Sakakibara T, Tonami H, Kitagawa Y and Miyazaki S: Transference of antibiotics into prostatic tissues: Sampling method by transurethral resection for the measurement of the concentration of antibiotics in the prostatic tissues. Hinyokika Kiyo. 32:969–975. 1986.PubMed/NCBI(In Japanese).
18	Falagas ME, Vouloumanou EK, Samonis G and Vardakas KZ: Fosfomycin. Clin Microbiol Rev. 29:321–347. 2016.PubMed/NCBI View Article : Google Scholar
19	Zykov IN, Samuelsen Ø, Jakobsen L, Småbrekke L, Andersson DI, Sundsfjord A and Frimodt-Møller N: Pharmacokinetics and pharmacodynamics of fosfomycin and its activity against extended-spectrum-β-lactamase-, plasmid-mediated AmpC-, and carbapenemase-producing Escherichia coli in a murine urinary tract infection model. Antimicrob Agents Chemother. 62:e02560–17. 2018.PubMed/NCBI View Article : Google Scholar
20	Michalopoulos AS, Livaditis IG and Gougoutas V: The revival of fosfomycin. Int J Infect Dis. 15:e732–e739. 2011.PubMed/NCBI View Article : Google Scholar
21	Okazaki M, Suzuki K, Asano N, Araki K, Shukuya N, Egami T, Higurashi Y, Morita K, Uchimura H and Watanabe T: Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother. 8:37–42. 2002.PubMed/NCBI View Article : Google Scholar
22	Takahashi K and Kanno H: Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 26:789–791. 1984.PubMed/NCBI View Article : Google Scholar
23	Sultan A, Rizvi M, Khan F, Sami H, Shukla I and Khan HM: Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urol Ann. 7:26–30. 2015.PubMed/NCBI View Article : Google Scholar
24	Vardakas KZ, Legakis NJ, Triarides N and Falagas ME: Susceptibility of contemporary isolates to fosfomycin: A systematic review of the literature. Int J Antimicrob Agents. 47:269–285. 2016.PubMed/NCBI View Article : Google Scholar
25	Castañeda-García A, Blázquez J and Rodríguez-Rojas A: Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics (Basel). 2:217–236. 2013.PubMed/NCBI View Article : Google Scholar
26	Mihailescu R, Furustrand Tafin U, Corvec S, Oliva A, Betrisey B, Borens O and Trampuz A: High activity of Fosfomycin and rifampin against methicillin-resistant Staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother. 58:2547–2553. 2014.PubMed/NCBI View Article : Google Scholar
27	Chai D, Liu X, Wang R, Bai Y and Cai Y: Efficacy of linezolid and fosfomycin in catheter-related biofilm infection caused by methicillin-resistant Staphylococcus aureus. Biomed Res Int. 2016(6413982)2016.PubMed/NCBI View Article : Google Scholar
28	Oliva A, Curtolo A, Volpicelli L, Cogliati Dezza F, De Angelis M, Cairoli S, Dell'Utri D, Goffredo BM, Raponi G and Venditti M: Synergistic meropenem/vaborbactam plus fosfomycin treatment of KPC producing K. Pneumoniae septic thrombosis unresponsive to ceftazidime/avibactam: From the bench to the bedside. Antibiotics (Basel). 10(781)2021.PubMed/NCBI View Article : Google Scholar
29	Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ and Shortridge D: Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against gram-negative bacterial strains by using time-kill curves. Antimicrob Agents Chemother. 63:e02549–18. 2019.PubMed/NCBI View Article : Google Scholar
30	Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, et al: Ceftazidime-avibactam in combination with fosfomycin: A novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa. J Infect Dis. 220:666–676. 2019.PubMed/NCBI View Article : Google Scholar
31	Cuba GT, Rocha-Santos G, Cayô R, Streling AP, Nodari CS, Gales AC, Pignatari ACC, Nicolau DP and Kiffer CRV: In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 75:1874–1878. 2020.PubMed/NCBI View Article : Google Scholar
32	Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK and Falagas ME: Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 31:695–701. 2012.PubMed/NCBI View Article : Google Scholar
33	Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, Vicchiarelli M and Louie A: The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob Agents Chemother. 62:e01682–18. 2018.PubMed/NCBI View Article : Google Scholar
34	Leelasupasri S, Santimaleeworagun W and Jitwasinkul T: Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant acinetobacter baumannii. J Pathog. 2018(3893492)2018.PubMed/NCBI View Article : Google Scholar
35	Zhao M, Bulman ZP, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, et al: Pharmacodynamics of colistin and fosfomycin: A ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 72:1985–1990. 2017.PubMed/NCBI View Article : Google Scholar
36	Lee YC, Chen PY, Wang JT and Chang SC: Prevalence of fosfomycin resistance and gene mutations in clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Resist Infect Control. 9(135)2020.PubMed/NCBI View Article : Google Scholar
37	Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E and Falagas ME: Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 53:4508–4510. 2009.PubMed/NCBI View Article : Google Scholar
38	Keating GM: Fosfomycin trometamol: A review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 73:1951–1966. 2013.PubMed/NCBI View Article : Google Scholar
39	Saltoglu N, Karali R, Yemisen M, Ozaras R, Balkan II, Mete B, Tabak F, Mert A, Hondur N and Ozturk R: Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities. Int J Clin Pract. 69:766–770. 2015.PubMed/NCBI View Article : Google Scholar
40	Liu HY, Lin HC, Lin YC, Yu SH, Wu WH and Lee YJ: Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect. 44:364–368. 2011.PubMed/NCBI View Article : Google Scholar
41	Karageorgopoulos DE, Wang R, Yu XH and Falagas ME: Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 67:255–268. 2012.PubMed/NCBI View Article : Google Scholar
42	European Society of Clinical Microbiology and Infectious Diseases Fosfomycin Trometamol-Rationale for the EUCAST Clinical Breakpoints, version 1.0, pp1-8, 2013.
43	van Mens SP, Ten Doesschate T, Kluytmans-van den Bergh MF, Mouton JW, Rossen JW, Verhulst C, Bonten MJ and Kluytmans JA: Fosfomycin etest for enterobacteriaceae: Interobserver and interlaboratory agreement. Int J Antimicrob Agents. 52:678–681. 2018.PubMed/NCBI View Article : Google Scholar
44	Karlowsky JA, Baxter MR, Golden AR, Adam HJ, Walkty A, Lagacé-Wiens PR and Zhanel GG: Use of fosfomycin etest to determine in vitro susceptibility of clinical isolates of enterobacterales other than Escherichia coli, nonfermenting gram-negative bacilli, and gram-positive cocci. J Clin Microbiol. 59(e0163521)2021.PubMed/NCBI View Article : Google Scholar
45	van den Bijllaardt W, Schijffelen MJ, Bosboom RW, Cohen Stuart J, Diederen B, Kampinga G, Le TN, Overdevest I, Stals F, Voorn P, et al: Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including etest, MIC test strip, Vitek2, phoenix and disc diffusion. J Antimicrob Chemother. 73:2380–2387. 2018.PubMed/NCBI View Article : Google Scholar
46	Aprile A, Scalia G, Stefani S and Mezzatesta ML: In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant enterobacteriaceae. J Glob Antimicrob Resist. 23:286–289. 2020.PubMed/NCBI View Article : Google Scholar
47	Campanile F, Wootton M, Davies L, Aprile A, Mirabile A, Pomponio S, Demetrio F, Bongiorno D, Walsh TR, Stefani S and Mezzatesta ML: Gold standard susceptibility testing of fosfomycin in Staphylococcus aureus and enterobacterales using a new agar dilution panel^®. J Glob Antimicrob Resist. 23:334–337. 2020.PubMed/NCBI View Article : Google Scholar
48	Parisio EM, Camarlinghi G, Coppi M, Niccolai C, Antonelli A, Nardone M, Vettori C, Giani T, Mattei R and Rossolini GM: Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant enterobacterales and Pseudomonas aeruginosa. Clin Microbiol Infect: Dec 4, 2020 (Epub ahead of print). doi: https://doi.org/10.1016/j.cmi.2020.11.029.
49	European Society of Clinical Microbiology and Infectious Diseases EUCAST: Clinical Breakpoints and Dosing of Antibiotics. Available from: https://www.eucast.org/clinical_breakpoints/. Accessed May 9, 2022.
50	Martín-Gutiérrez G, Docobo-Pérez F, Rodríguez-Martínez JM, Pascual A, Blázquez J and Rodriguez-Beltrán J: Detection of low-level fosfomycin-resistant variants by decreasing glucose-6-phosphate concentration in fosfomycin susceptibility determination. Antibiotics (Basel). 9(802)2020.PubMed/NCBI View Article : Google Scholar
51	Cattoir V and Guérin F: How is fosfomycin resistance developed in Escherichia coli? Future Microbiol. 13:1693–1696. 2018.PubMed/NCBI View Article : Google Scholar
52	Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D, Alivizatos G and Giamarellou E: Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 74:1430–1437. 2019.PubMed/NCBI View Article : Google Scholar
53	Denes E: Prolonged course of fosfomycin-trometamol for chronic prostatitis: An unknown good option. Scand J Urol. 55:344–345. 2021.PubMed/NCBI View Article : Google Scholar
54	Cai T, Tamanini I, Mattevi D, Verze P, Palmieri A, Malossini G, Mirone V, Novelli A, Tascini C and Johansen TE: Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study. Int J Antimicrob Agents. 56(105935)2020.PubMed/NCBI View Article : Google Scholar
55	Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Fernández-Hidalgo N, Andreu A, Larrosa N and Almirante B: Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis. Antimicrob Agents Chemother. 60:1854–1858. 2015.PubMed/NCBI View Article : Google Scholar
56	Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, Gardiner BJ and Frauman AG: Fosfomycin for treatment of prostatitis: New tricks for old dogs. Clin Infect Dis. 61:1141–1143. 2015.PubMed/NCBI View Article : Google Scholar
57	Shrestha NK, Amuh D, Goldman M, Riebel WJ and Walton*Tomford J: Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Pract. 9:368–371. 2000.
58	Celesia BM, Marino A, Borracino S, Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo B and Panarello G: Successful extracorporeal membrane oxygenation treatment in an acquired immune deficiency syndrome (AIDS) patient with acute respiratory distress syndrome (ARDS) complicating pneumocystis jirovecii pneumonia: A challenging case. Am J Case Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar
59	Matsumoto M and Yamamoto S: AAUS guideline for acute bacterial prostatitis 2021. J Infect Chemother. 27:1277–1283. 2021.PubMed/NCBI View Article : Google Scholar
60	Marino A, Cosentino F, Ceccarelli M, Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G, Benanti F, et al: Entecavir resistance in a patient with treatment-naïve HBV: A case report. Mol Clin Oncol. 14(113)2021.PubMed/NCBI View Article : Google Scholar
61	Celesia BM, Marino A, Del Vecchio RF, Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it safe and cost saving to defer the CD4⁺ cell count monitoring in stable patients on art with more than 350 or 500 cells/µl? Mediterr J Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar